Global Health Improvement Targets Announced On World Aspergillosis Day February 1st 2018

Prof. David Denning GAFFI President

Nothing less than a concerted international effort is required to address huge disparities in aspergillosis frequency”

— Professor David Denning

LISBON, LISBON, PORTUGAL, January 31, 2018 /EINPresswire.com/ — Aspergillosis, lung and sinus disease caused by the fungus Aspergillus, affects around 15 million people and kills over 1 million each year. Announced today at the 8th biennial Advances against Aspergillosis international conference in Lisbon starting on February 1st, are the 5 aspirational targets for aspergillosis to be achieved by 2030:

1. Survival in invasive aspergillosis increased to 90% (up from under 50%)
2. Plugging the major gaps in our understanding of the biological, immunological and genetic basis of aspergillosis
3. Diagnostics (most countries, including all of Africa have no diagnostic capability at all)
• New widely available, standardized and clinically validated diagnostics techniques
• New simple screening tests developed
4. Treatment
• New antifungal agents licensed for invasive, chronic and allergic aspergillosis and for all age groups (only 3 classes currently available)
5. At least one vaccine against aspergillosis in clinical trials or approved (none currently).

At the conference opening session, Professor David Denning, President of the Global Action Fund for Fungal Diseases (GAFFI) and Professor of Infectious Diseases in Global Health at the University of Manchester spoke on behalf of patients, doctors and researchers in calling for radical improvements. Because diagnostics are not available in so many countries, hundreds of thousands of people unknowingly die or are disabled by aspergillosis yet could be saved or cured. He said: “I have been looking after patients with aspergillosis for over 35 years, and yet we still lose patients and see too many people severely affected by this common fungus. I contributed to many clinical studies bringing the first effective oral drugs to patients (itraconazole and voriconazole), and yet the burden and deaths remains huge. Nothing less than a concerted international effort is required to address huge disparities in aspergillosis frequency.”

2018 marks the 20th anniversary of The Aspergillus Website, which the Fungal Infection Trust has been supporting. It provides a truly encyclopedic resource (>100,000 pages) and news feed to the world at no cost to the user, thanks to its many supporters over decades. Together with its sister Website for Patients, they attract over 125.000 users per month, indicative of the need for information. In 2012, the Fungal Infection Trust launched a global educational website Life Worldwide, in English and Spanish, which is also highly utilised.

The Advances in Aspergillosis conference series, held alternate years, is the premier forum for detailed and dedicated discussion of all aspects of aspergillosis, attracting over 350 delegates from 35+ countries. Topical issues include: emergence of pan-azole and echinocandin resistance which requires unique approaches, new antifungal agents and immunotherapies for chronic and allergic aspergillosis, better molecular and low-cost strategies for diagnosis and publication of several recent clinical guidelines for clinicians offer detailed guidance.

Other major needs for health improvements in aspergillosis include:
• Improvement in the public’s awareness of fungal diseases and specifically aspergillosis
• Keeping homes free from excessive Aspergillus and other moulds related to dampness, which increases the number and severity of asthma episodes
• Stronger evidence base of antifungal therapy allergic aspergillosis to reduce the number and severity of asthma episodes, and probably asthma deaths
• Hospital environments for vulnerable patients free of Aspergillus
• Reduction in azole resistance with reduced use of azole fungicides in non-essential crops
• Prevention of a new epidemic of resistance with any new classes of antifungal used for aspergillosis by not allowing such chemical class to be used as a fungicide
• Need for better surveillance and detailed epidemiology data
• Development of immunotherapies as well as vaccines

Luisa Morlano
The Goodwork Organisation Ltd
+442087471488
email us here


Source: EIN Presswire

IT Governance launches ISO 27001 webinar series to support organizations with ISMS implementation

IT Governance, the global cybersecurity experts.

NEW YORK, UNITED STATES, January 31, 2018 /EINPresswire.com/ — IT Governance, the leading provider of information security and General Data Protection Regulation (GDPR) expertise and training, and a globally recognized authority on ISO 27001, is delighted to announce the launch of new webinars on ISO 27001 compliance.

As the number of cyber attacks continues to rise and data security laws and regulations become more stringent, businesses are under increasing pressure to protect their systems from cyber attacks, slip-ups, and data misuse. But the challenge of complying with multiple cybersecurity regulations is considerable. With little guidance on how to achieve a robust data security posture, organizations are struggling to find a comprehensive solution that can assure compliance.

ISO/IEC 27001:2013 (ISO 27001) is the international standard that describes best practice for an information security management system (ISMS). Achieving accredited certification to ISO 27001 demonstrates that your company is following information security best practice, and provides an independent, expert verification that information security is being managed in line with international best practice and business objectives.

IT Governance’s free new webinars will share valuable insight into information security problem-solving. The first webinar aims to provide an overview of the current cybersecurity landscape and the latest data protection laws, and to highlight how an ISMS can help create the best strategies to mitigate breaches and meet even the most stringent of compliance standards.

Alan Calder, the founder and executive chairman of IT Governance, said: “New York financial organizations can not only meet the New York State Department of Financial Services (NYDFS) requirements but also ensure they are prepared in an ever-changing cybersecurity landscape by implementing ISO 27001, the internationally recognized information security management standard.

“The aim of our new ISO 27001 webinars is to introduce the Standard and its implementation step by step, as well as to prepare organizations for their toughest data security challenges yet.”

The first webinar, How to overcome your data security compliance challenges, goes live on February 15 at 10:00 am (EST)/1:00 pm (PST). It will be followed by:

– How to implement an information security management system
– Conducting a cybersecurity risk assessment
– Assessing compliance: the ISO 27001 ISMS internal audit

To read more about each webinar, please visit our webinar page. To discuss your cybersecurity requirements, contact our consultancy team at servicecenter@itgovernanceusa.com, or request a call.

Mihaela Jucan
IT Governance Ltd
00443338007000
email us here


Source: EIN Presswire

Digital X-Ray Systems Market 2018 Segmentation, Application, Technology and Analysis Forecast to 2023

Wiseguyreports.Com Publish New Market Research Report On -“Digital X-Ray Systems Market – Global Analysis, Size, Share, Trends, Growth and Forecast 2018 – 2023”

PUNE, INDIA, January 31, 2018 /EINPresswire.com/ —

Digital X-Ray Systems 2018

The Digital X-Ray Systems industry has also suffered a certain impact, but still maintained a relatively optimistic growth. The past four years, Digital X-Ray Systems market size maintained the average annual growth rate of xx% from xxx million $ in 2013 to xxx million $ in 2016. The analysts believe that in the next few years, Digital X-Ray Systems market size will be further expanded, we expect that by 2021, the market size of the Digital X-Ray Systems will reach xxx million $.

This Report covers the manufacturers’ data, including: shipment, price, revenue, gross profit, interview record, business distribution etc., these data help the consumer know about the competitors better. This report also covers all the regions and countries of the world, which shows a regional development status, including market size, volume and value, as well as price data.

Request a Sample Report @ https://www.wiseguyreports.com/sample-request/2866534-global-digital-x-ray-systems-market-report-2017

Besides, the report also covers segment data, including: type segment, industry segment, channel segment etc. cover different segment market size, both volume and value. Also cover different industries clients information, which is very important for the manufacturers.

Section 1: Free——Definition
Section (2 3): 1200 USD——Manufacturer Detail
GE Healthcare
Siemens Healthcare
Philips Healthcare
Fujifilm
Carestream Health
Agfa HealthCare
Hitachi
Toshiba
Konica Minolta
Shimadzu
Source-Ray
KUB Technologies

Section 4: 900 USD——Region Segmentation
North America Country (United States, Canada)
South America
Asia Country (China, Japan, India, Korea)
Europe Country (Germany, UK, France, Italy)
Other Country (Middle East, Africa, GCC)
Section (5 6 7): 500 USD——
Product Type Segmentation (CR Tech, DR Tech)
Industry Segmentation (Urgent Care, Orthopedics, Chiropractic, Other)
Channel (Direct Sales, Distributor) Segmentation

Section 8: 400 USD——Trend (2017-2021)
Section 9: 300 USD——Product Type Detail
Section 10: 700 USD——Downstream Consumer
Section 11: 200 USD——Cost Structure
Section 12: 500 USD——Conclusion

Complete Report Details @ https://www.wiseguyreports.com/reports/2866534-global-digital-x-ray-systems-market-report-2017

Table of Contents –Analysis of Key Points

Section 1 Digital X-Ray Systems Product Definition
Section 2 Global Digital X-Ray Systems Market Manufacturer Share and Market Overview
2.1 Global Manufacturer Digital X-Ray Systems Shipments
2.2 Global Manufacturer Digital X-Ray Systems Business Revenue
2.3 Global Digital X-Ray Systems Market Overview

Section 3 Manufacturer Digital X-Ray Systems Business Introduction
3.1 GE Healthcare Digital X-Ray Systems Business Introduction
3.1.1 GE Healthcare Digital X-Ray Systems Shipments, Price, Revenue and Gross profit 2013-2016
3.1.2 GE Healthcare Digital X-Ray Systems Business Distribution by Region
3.1.3 GE Healthcare Interview Record
3.1.4 GE Healthcare Digital X-Ray Systems Business Profile
3.1.5 GE Healthcare Digital X-Ray Systems Product Specification
3.2 Siemens Healthcare Digital X-Ray Systems Business Introduction
3.2.1 Siemens Healthcare Digital X-Ray Systems Shipments, Price, Revenue and Gross profit 2013-2016
3.2.2 Siemens Healthcare Digital X-Ray Systems Business Distribution by Region
3.2.3 Interview Record
3.2.4 Siemens Healthcare Digital X-Ray Systems Business Overview
3.2.5 Siemens Healthcare Digital X-Ray Systems Product Specification
3.3 Philips Healthcare Digital X-Ray Systems Business Introduction
3.3.1 Philips Healthcare Digital X-Ray Systems Shipments, Price, Revenue and Gross profit 2013-2016
3.3.2 Philips Healthcare Digital X-Ray Systems Business Distribution by Region
3.3.3 Interview Record
3.3.4 Philips Healthcare Digital X-Ray Systems Business Overview
3.3.5 Philips Healthcare Digital X-Ray Systems Product Specification
3.4 Fujifilm Digital X-Ray Systems Business Introduction
3.5 Carestream Health Digital X-Ray Systems Business Introduction
3.6 Agfa HealthCare Digital X-Ray Systems Business Introduction

Section 4 Global Digital X-Ray Systems Market Segmentation (Region Level)
Section 5 Global Digital X-Ray Systems Market Segmentation (Product Type Level)
5.1 Global Digital X-Ray Systems Market Segmentation (Product Type Level) Market Size 2013-2016
5.2 Different Digital X-Ray Systems Product Type Price 2013-2016
5.3 Global Digital X-Ray Systems Market Segmentation (Product Type Level) Analysis

Section 6 Global Digital X-Ray Systems Market Segmentation (Industry Level)
6.1 Global Digital X-Ray Systems Market Segmentation (Industry Level) Market Size 2013-2016
6.2 Different Industry Price 2013-2016
6.3 Global Digital X-Ray Systems Market Segmentation (Industry Level) Analysis

Section 7 Global Digital X-Ray Systems Market Segmentation (Channel Level)
7.1 Global Digital X-Ray Systems Market Segmentation (Channel Level) Sales Volume and Share 2013-2016
7.2 Global Digital X-Ray Systems Global Digital X-Ray Systems Market Segmentation (Channel Level) Analysis

Section 8 Digital X-Ray Systems Market Forecast 2017-2021
8.1 Digital X-Ray Systems Segmentation Market Forecast (Region Level)
8.2 Digital X-Ray Systems Segmentation Market Forecast (Product Type Level)
8.3 Digital X-Ray Systems Segmentation Market Forecast (Industry Level)
8.4 Digital X-Ray Systems Segmentation Market Forecast (Channel Level)

Section 9 Digital X-Ray Systems Segmentation Product Type
9.1 CR Tech Product Introduction
9.2 DR Tech Product Introduction

Section 10 Digital X-Ray Systems Segmentation Industry
10.1 Urgent Care Clients
10.2 Orthopedics Clients
10.3 Chiropractic Clients
10.4 Other Clients

Section 11 Digital X-Ray Systems Cost of Production Analysis
11.1 Raw Material Cost Analysis
11.2 Technology Cost Analysis
11.3 Labor Cost Analysis
11.4 Cost Overview

Section 12 Conclusion
..…..Continued

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Global Bacterial Vaginosis Drugs and Companies Pipeline Review H1 2018

Bacterial Vaginosis Assessment and Therapeutics Pipeline Review H1 2018

PUNE, INDIA, January 31, 2018 /EINPresswire.com/ — Summary
Bacterial vaginosis (BV), also known as vaginal bacteriosis is a type of vaginal inflammation caused by overgrowth of bacteria present in vagina. Symptoms include vaginal itching; burning during urination and vaginal discharge may become watery and thin. Treatment includes antibiotics.

Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Bacterial Vaginosis – Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Bacterial Vaginosis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/2841820-bacterial-vaginosis-pipeline-review-h1-2018

The Bacterial Vaginosis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Bacterial Vaginosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 1, 5, 1, 2 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Bacterial Vaginosis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope
– The pipeline guide provides a snapshot of the global therapeutic landscape of Bacterial Vaginosis (Infectious Disease).
– The pipeline guide reviews pipeline therapeutics for Bacterial Vaginosis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Bacterial Vaginosis (Infectious Disease) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Bacterial Vaginosis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Bacterial Vaginosis (Infectious Disease)

Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Bacterial Vaginosis (Infectious Disease).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Bacterial Vaginosis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Content: Key Points
List of Tables
List of Figures
Introduction
Bacterial Vaginosis – Overview
Bacterial Vaginosis – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Bacterial Vaginosis – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Bacterial Vaginosis – Companies Involved in Therapeutics Development
Evofem Inc
Osel Inc
Pharmiva AB
Profarma
Starpharma Holdings Ltd
Bacterial Vaginosis – Drug Profiles
…Continued

ACCESS REPORT @ https://www.wiseguyreports.com/reports/2841820-bacterial-vaginosis-pipeline-review-h1-2018

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Advanced Wound Care Management Market 2018 Global Analysis, Growth, Size, Trends, Segmentation Forecast To 2025

“Advanced Wound Care Management – Global Market Demand, Growth, Opportunities, Manufacturers, Analysis of Top Key Players and Forecast to 2025”

PUNE, MAHARASHTRA, INDIA, January 31, 2018 /EINPresswire.com/ — Advanced Wound Care Management Market 2018    

Description: 

In this report, the global Advanced Wound Care Management market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025.

Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Advanced Wound Care Management in these regions, from 2013 to 2025 (forecast), covering 
North America 
Europe 
China 
Japan 
Southeast Asia 
India 
Global Advanced Wound Care Management market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer; the top players including 
Coloplast A/S 
Medline Industries 
Medtronic 
Smith & Nephew 
ConvaTec 
Organogenesis 
B. Braun Melsungen AG 
Acelity L.P. Inc. 
3M 
BSN medical GmbH 
Molnlycke Health Care 

Request for Sample Report@ https://www.wiseguyreports.com/sample-request/2842407-global-advanced-wound-care-management-market-research-report-2018

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into 
Moist Wound Dressings 
Active Wound Care 
Therapy Devices 
On the basis of the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including 
Epidemiology 
Burns 
Ulcers 
Surgical Wounds 
Others

Enquiry before Buying @ https://www.wiseguyreports.com/enquiry/2842407-global-advanced-wound-care-management-market-research-report-2018

If you have any special requirements, please let us know and we will offer you the report as you want.

Table of Contents:

Global Advanced Wound Care Management Market Research Report 2018 
1 Advanced Wound Care Management Market Overview 
1.1 Product Overview and Scope of Advanced Wound Care Management 
1.2 Advanced Wound Care Management Segment by Type (Product Category) 
1.2.1 Global Advanced Wound Care Management Production and CAGR (%) Comparison by Type (Product Category)(2013-2025) 
1.2.2 Global Advanced Wound Care Management Production Market Share by Type (Product Category) in 2017
1.2.3 Moist Wound Dressings 
1.2.4 Active Wound Care 
1.2.5 Therapy Devices 
1.3 Global Advanced Wound Care Management Segment by Application 
1.3.1 Advanced Wound Care Management Consumption (Sales) Comparison by Application (2013-2025) 
1.3.2 Epidemiology 
1.3.3 Burns 
1.3.4 Ulcers 
1.3.5 Surgical Wounds 
1.3.6 Others 
1.4 Global Advanced Wound Care Management Market by Region (2013-2025) 
1.4.1 Global Advanced Wound Care Management Market Size (Value) and CAGR (%) Comparison by Region (2013-2025) 
1.4.2 North America Status and Prospect (2013-2025) 
1.4.3 Europe Status and Prospect (2013-2025) 
1.4.4 China Status and Prospect (2013-2025) 
1.4.5 Japan Status and Prospect (2013-2025) 
1.4.6 Southeast Asia Status and Prospect (2013-2025) 
1.4.7 India Status and Prospect (2013-2025) 
1.5 Global Market Size (Value) of Advanced Wound Care Management (2013-2025) 
1.5.1 Global Advanced Wound Care Management Revenue Status and Outlook (2013-2025) 
1.5.2 Global Advanced Wound Care Management Capacity, Production Status and Outlook (2013-2025)

2 Global Advanced Wound Care Management Market Competition by Manufacturers 
2.1 Global Advanced Wound Care Management Capacity, Production and Share by Manufacturers (2013-2018) 
2.1.1 Global Advanced Wound Care Management Capacity and Share by Manufacturers (2013-2018) 
2.1.2 Global Advanced Wound Care Management Production and Share by Manufacturers (2013-2018) 
2.2 Global Advanced Wound Care Management Revenue and Share by Manufacturers (2013-2018) 
2.3 Global Advanced Wound Care Management Average Price by Manufacturers (2013-2018) 
2.4 Manufacturers Advanced Wound Care Management Manufacturing Base Distribution, Sales Area and Product Type 
2.5 Advanced Wound Care Management Market Competitive Situation and Trends 
2.5.1 Advanced Wound Care Management Market Concentration Rate 
2.5.2 Advanced Wound Care Management Market Share of Top 3 and Top 5 Manufacturers 
2.5.3 Mergers & Acquisitions, Expansion

……. 

7 Global Advanced Wound Care Management Manufacturers Profiles/Analysis 
7.1 Coloplast A/S 
7.1.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 
7.1.2 Advanced Wound Care Management Product Category, Application and Specification 
7.1.2.1 Product A 
7.1.2.2 Product B 
7.1.3 Coloplast A/S Advanced Wound Care Management Capacity, Production, Revenue, Price and Gross Margin (2013-2018) 
7.1.4 Main Business/Business Overview 
7.2 Medline Industries 
7.2.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 
7.2.2 Advanced Wound Care Management Product Category, Application and Specification 
7.2.2.1 Product A 
7.2.2.2 Product B 
7.2.3 Medline Industries Advanced Wound Care Management Capacity, Production, Revenue, Price and Gross Margin (2013-2018) 
7.2.4 Main Business/Business Overview 
7.3 Medtronic 
7.3.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 
7.3.2 Advanced Wound Care Management Product Category, Application and Specification 
7.3.2.1 Product A 
7.3.2.2 Product B 
7.3.3 Medtronic Advanced Wound Care Management Capacity, Production, Revenue, Price and Gross Margin (2013-2018) 
7.3.4 Main Business/Business Overview 
7.4 Smith & Nephew 
7.4.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 
7.4.2 Advanced Wound Care Management Product Category, Application and Specification 
7.4.2.1 Product A 
7.4.2.2 Product B 
7.4.3 Smith & Nephew Advanced Wound Care Management Capacity, Production, Revenue, Price and Gross Margin (2013-2018) 
7.4.4 Main Business/Business Overview 
7.5 ConvaTec 
7.5.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 
7.5.2 Advanced Wound Care Management Product Category, Application and Specification 
7.5.2.1 Product A 
7.5.2.2 Product B 
7.5.3 ConvaTec Advanced Wound Care Management Capacity, Production, Revenue, Price and Gross Margin (2013-2018) 
7.5.4 Main Business/Business Overview 
7.6 Organogenesis 
7.6.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 
7.6.2 Advanced Wound Care Management Product Category, Application and Specification 
7.6.2.1 Product A 
7.6.2.2 Product B 
7.6.3 Organogenesis Advanced Wound Care Management Capacity, Production, Revenue, Price and Gross Margin (2013-2018) 
7.6.4 Main Business/Business Overview 
7.7 B. Braun Melsungen AG 
7.7.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 
7.7.2 Advanced Wound Care Management Product Category, Application and Specification 
7.7.2.1 Product A 
7.7.2.2 Product B 
7.7.3 B. Braun Melsungen AG Advanced Wound Care Management Capacity, Production, Revenue, Price and Gross Margin (2013-2018) 
7.7.4 Main Business/Business Overview 
7.8 Acelity L.P. Inc. 
7.8.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 
7.8.2 Advanced Wound Care Management Product Category, Application and Specification 
7.8.2.1 Product A 
7.8.2.2 Product B 
7.8.3 Acelity L.P. Inc. Advanced Wound Care Management Capacity, Production, Revenue, Price and Gross Margin (2013-2018) 
7.8.4 Main Business/Business Overview 
7.9 3M 
7.10 BSN medical GmbH 
7.11 Molnlycke Health Care

Continued…..

Buy now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=2842407

Norah Trent
WiseGuy Research Consultants Pvt. Ltd.
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Warts Pharmaceutical and Healthcare Analysis Information

Warts Assessment and Therapeutics Pipeline Review H1 2018

PUNE, INDIA, January 31, 2018 /EINPresswire.com/ — Summary
Warts are skin growth that is caused by virus called human papillomavirus (HPV). HPV infects the top layer of skin, usually entering the body in an area of broken skin. The virus causes the top layer of skin to grow rapidly, forming a wart. Symptoms include pain and rough skin. Predisposing factors include age and people with weakened immune systems, such as those with HIV/AIDS or people who had organ transplants.

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/2841819-warts-pipeline-review-h1-2018

Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Warts – Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Warts (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Warts (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Warts and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 16, 2, 5, 2 and 1 respectively. Similarly, the Universities portfolio in Phase II stages comprises 2 molecules, respectively.

Warts (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope
– The pipeline guide provides a snapshot of the global therapeutic landscape of Warts (Infectious Disease).
– The pipeline guide reviews pipeline therapeutics for Warts (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Warts (Infectious Disease) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Warts (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Warts (Infectious Disease)

Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Warts (Infectious Disease).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Warts (Infectious Disease) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Content: Key Points
List of Tables
List of Figures
Introduction
Warts – Overview
Warts – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Warts – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Warts – Companies Involved in Therapeutics Development
Aclaris Therapeutics Inc
Agilvax Inc
Aviragen Therapeutics Inc
BioMAS Ltd
Cadila Healthcare Ltd
Cutanea Life Sciences Inc
Cytovation AS
G&E Herbal Biotechnology Co Ltd
Genetic Immunity Inc
Laboratories Ojer Pharma SL
LEO Pharma A/S
Nielsen Biosciences Inc
…Continued

ACCESS REPORT @ https://www.wiseguyreports.com/reports/2841819-warts-pipeline-review-h1-2018

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Global Community Acquired Pneumonia Drugs and Companies Pipeline Review H1 2018

Community Acquired Pneumonia Pharmaceutical and Healthcare Pipeline Review H1

PUNE, INDIA, January 31, 2018 /EINPresswire.com/ — Summary
Community-acquired pneumonia (CAP) is defined as pneumonia acquired outside a hospital or long-term care facility. Symptoms include cough, fever, shaking chills, confusion, headache and loss of appetite. Risk factors include chronic lung disease, cigarette smoking, dementia, stroke, brain injury, heart disease, liver cirrhosis and diabetes mellitus. Treatment includes antibiotics and healthy lifestyle.

Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Community Acquired Pneumonia – Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Community Acquired Pneumonia (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/2841816-community-acquired-pneumonia-pipeline-review-h1-2018

The Community Acquired Pneumonia (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Community Acquired Pneumonia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 4, 1, 2, 6, 2, 2 and 1 respectively.

Community Acquired Pneumonia (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope
– The pipeline guide provides a snapshot of the global therapeutic landscape of Community Acquired Pneumonia (Infectious Disease).
– The pipeline guide reviews pipeline therapeutics for Community Acquired Pneumonia (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Community Acquired Pneumonia (Infectious Disease) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Community Acquired Pneumonia (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Community Acquired Pneumonia (Infectious Disease)

Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Community Acquired Pneumonia (Infectious Disease).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Community Acquired Pneumonia (Infectious Disease) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Content: Key Points
List of Tables
List of Figures
Introduction
Community Acquired Pneumonia – Overview
Community Acquired Pneumonia – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Community Acquired Pneumonia – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Community Acquired Pneumonia – Companies Involved in Therapeutics Development
Biotest AG
InflaRx NV
ioGenetics Inc
Kyorin Pharmaceutical Co Ltd
Meiji Seika Pharma Co Ltd
Melinta Therapeutics Inc
Merck & Co Inc
Nabriva Therapeutics plc
Paratek Pharmaceuticals Inc
ProThera Biologics Inc
…Continued

ACCESS REPORT @ https://www.wiseguyreports.com/reports/2841816-community-acquired-pneumonia-pipeline-review-h1-2018

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Global Cosmetics Market 2018 Segmentation, Demand, Growth, Trend, Opportunity And Forecast To 2021

Wiseguyreports.Com Adds “Cosmetics – Global Market Demand, Growth, Opportunities, Manufacturers, Analysis of Top Key Players and Forecast to 2021”

PUNE, MAHARASHTRA, INDIA, January 31, 2018 /EINPresswire.com/ — Cosmetics Market 2018 

Description: 

Cosmetics Report by Material, Application, and Geography – Global Forecast to 2021 is a professional and comprehensive research report on the world's major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, United Kingdom,Japan, South Korea and China).

In this report, the global Cosmetics market is valued at USD XX million in 2017 and is projected to reach USD XX million by the end of 2021, growing at a CAGR of XX% during the period 2017 to 2021.

The report firstly introduced the Cosmetics basics: definitions, classifications, applications and market overview; product specifications; manufacturing processes; cost structures, raw materials and so on. Then it analyzed the world's main region market conditions, including the product price, profit, capacity, production, supply, demand and market growth rate and forecast etc. In the end, the report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis.

The major players profiled in this report include: 
inoherb 
Pechoin 
Olay 
Maybelline 
L'Oréal 
Lakme 

Request for Sample Report@ https://www.wiseguyreports.com/sample-request/2873166-global-cosmetics-market-size-and-forecast-to-2021

The end users/applications and product categories analysis: 
On the basis of product, this report displays the sales volume, revenue (Million USD), product price, market share and growth rate of each type, primarily split into- 
Skin & Sun Care Products 
Hair Care Products 
Others 

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Cosmetics for each application, including- 
General departmental store 
Supermarkets 
Others

Enquiry before Buying @ https://www.wiseguyreports.com/enquiry/2873166-global-cosmetics-market-size-and-forecast-to-2021

If you have any special requirements, please let us know and we will offer you the report as you want.

Table of Contents:

Part I Cosmetics Industry Overview

Chapter One Cosmetics Industry Overview 
    1.1 Cosmetics Definition 
    1.2 Cosmetics Classification and Prodcut Type Analysis 
Skin & Sun Care Products 
Hair Care Products 
Others 
…… 
    1.3 Cosmetics Application and Down Stream Market Analysis 
General departmental store 
Supermarkets 
Others 
…… 
    1.4 Cosmetics Industry Chain Structure Analysis 
    1.5 Cosmetics Industry Development Overview 
    1.6 Cosmetics Global Market Comparison Analysis 
      1.6.1 Cosmetics Global Import Market Analysis 
      1.6.2 Cosmetics Global Export Market Analysis 
      1.6.3 Cosmetics Global Main Region Market Analysis 
      1.6.4 Cosmetics Global Market Comparison Analysis 
      1.6.5 Cosmetics Global Market Development Trend Analysis

Part II Asia Cosmetics Industry (The Report Company Including the Below Listed But Not All)

Chapter Two 2012-2017 Asia Cosmetics Productions Supply Sales Demand Market Status and Forecast 
    2.1 2012-2017 Cosmetics Capacity Production Overview 
    2.2 2012-2017 Cosmetics Production Market Share Analysis 
    2.3 2012-2017 Cosmetics Demand Overview 
    2.4 2012-2017 Cosmetics Supply Demand and Shortage Analysis 
    2.5 2012-2017 Cosmetics Import Export Consumption Analysis 
    2.6 2012-2017 Cosmetics Cost Price Production Value Profit Analysis

Chapter Three Asia Cosmetics Key Manufacturers Analysis 
    3.1 inoherb 
      3.1.1 Product Picture and Specification 
      3.1.2 Capacity Production Price Cost Production Value Analysis 
      3.1.3 Contact Information

    3.2 Pechoin 
      3.2.1 Product Picture and Specification 
      3.2.2 Capacity Production Price Cost Production Value Analysis 
      3.2.3 Contact Information

    3.3 Company C 
      3.3.1 Product Picture and Specification 
      3.3.2 Capacity Production Price Cost Production Value Analysis 
      3.3.3 Contact Information 
… 
… 
Chapter Four Asia Cosmetics Industry Development Trend 
    4.1 2017-2021 Cosmetics Capacity Production Trend 
    4.2 2017-2021 Cosmetics Production Market Share Analysis 
    4.3 2017-2021 Cosmetics Demand Trend 
    4.4 2017-2021 Cosmetics Supply Demand and Shortage Analysis 
    4.5 2017-2021 Cosmetics Import Export Consumption Analysis 
    4.6 2017-2021 Cosmetics Cost Price Production Value Profit Analysis

Part III North American Cosmetics Industry (The Report Company Including the Below Listed But Not All)

Chapter Five 2012-2017 North American Cosmetics Productions Supply Sales Demand Market Status and Forecast 
    5.1 2012-2017 Cosmetics Capacity Production Overview 
    5.2 2012-2017 Cosmetics Production Market Share Analysis 
    5.3 2012-2017 Cosmetics Demand Overview 
    5.4 2012-2017 Cosmetics Supply Demand and Shortage Analysis 
    5.5 2012-2017 Cosmetics Import Export Consumption Analysis 
    5.6 2012-2017 Cosmetics Cost Price Production Value Profit Analysis

Chapter Six North American Cosmetics Key Manufacturers Analysis 
    6.1 Olay 
      6.1.1 Product Picture and Specification 
      6.1.2 Capacity Production Price Cost Production Value Analysis 
      6.1.3 Contact Information

    6.2 Maybelline 
      6.2.1 Product Picture and Specification 
      6.2.2 Capacity Production Price Cost Production Value Analysis 
      6.2.3 Contact Information 

 …….

Chapter Nine Europe Cosmetics Key Manufacturers Analysis 
    9.1 L'Oréal 
      9.1.1 Product Picture and Specification 
      9.1.2 Capacity Production Price Cost Production Value Analysis 
      9.1.3 Contact Information

    9.2 Lakme 
      9.2.1 Product Picture and Specification 
      9.2.2 Capacity Production Price Cost Production Value Analysis 
      9.2.3 Contact Information 

 Continued…..

Buy now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=2873166

Norah Trent
WiseGuy Research Consultants Pvt. Ltd.
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Dental CAD/CAM Milling Machines – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2018 – 2023

Dental CAD/CAM Milling Machines Market 2018 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting to 2023

PUNE, MAHARASHTRA, INDIA, January 31, 2018 /EINPresswire.com/ — Summary

WiseGuyReports.com adds “Dental CAD/CAM Milling Machines Market 2018 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting to 2023” reports to its database.

This report provides in depth study of “Dental CAD/CAM Milling Machines Market” using SWOT analysis i.e. Strength, Weakness, Opportunities and Threat to the organization. The Dental CAD/CAM Milling Machines Market report also provides an in-depth survey of key players in the market which is based on the various objectives of an organization such as profiling, the product outline, the quantity of production, required raw material, and the financial health of the organization.

This report studies Dental CAD/CAM Milling Machines in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022.

This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering
Dentsply Sirona
Ivoclar Vivadent
Roland
Straumann
Zimmer
Zirkonzahn
Willemin-Macodel
Dentium
Amann Girrbach
Imes-icore
DATRON
Schutz Dental
vhf camfacture
Yenadent
B&D Dental
INTERDENT
MECANUMERIC
CadBlu Dental
Bien-Air Dental
Reitel Feinwerktechnik

Request a Sample Report @ https://www.wiseguyreports.com/sample-request/2785058-global-dental-cad-cam-milling-machines-market-professional-survey-report

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
4 Axis
5 Axis
Others

By Application, the market can be split into
Dental Clinic
Dental Lab
Others

By Regions, this report covers (we can add the regions/countries as you want)
North America
China
Europe
Southeast Asia
Japan
India

At any Query @ https://www.wiseguyreports.com/enquiry/2785058-global-dental-cad-cam-milling-machines-market-professional-survey-report

Table of Contents

Global Dental CAD/CAM Milling Machines Market Professional Survey Report 2017
1 Industry Overview of Dental CAD/CAM Milling Machines
1.1 Definition and Specifications of Dental CAD/CAM Milling Machines
1.1.1 Definition of Dental CAD/CAM Milling Machines
1.1.2 Specifications of Dental CAD/CAM Milling Machines
1.2 Classification of Dental CAD/CAM Milling Machines
1.2.1 4 Axis
1.2.2 5 Axis
1.2.3 Others
1.3 Applications of Dental CAD/CAM Milling Machines
1.3.1 Dental Clinic
1.3.2 Dental Lab
1.3.3 Others
1.4 Market Segment by Regions
1.4.1 North America
1.4.2 China
1.4.3 Europe
1.4.4 Southeast Asia
1.4.5 Japan
1.4.6 India

2 Manufacturing Cost Structure Analysis of Dental CAD/CAM Milling Machines
2.1 Raw Material and Suppliers
2.2 Manufacturing Cost Structure Analysis of Dental CAD/CAM Milling Machines
2.3 Manufacturing Process Analysis of Dental CAD/CAM Milling Machines
2.4 Industry Chain Structure of Dental CAD/CAM Milling Machines

…..

8 Major Manufacturers Analysis of Dental CAD/CAM Milling Machines
8.1 Dentsply Sirona
8.1.1 Company Profile
8.1.2 Product Picture and Specifications
8.1.2.1 Product A
8.1.2.2 Product B
8.1.3 Dentsply Sirona 2016 Dental CAD/CAM Milling Machines Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.1.4 Dentsply Sirona 2016 Dental CAD/CAM Milling Machines Business Region Distribution Analysis
8.2 Ivoclar Vivadent
8.2.1 Company Profile
8.2.2 Product Picture and Specifications
8.2.2.1 Product A
8.2.2.2 Product B
8.2.3 Ivoclar Vivadent 2016 Dental CAD/CAM Milling Machines Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.2.4 Ivoclar Vivadent 2016 Dental CAD/CAM Milling Machines Business Region Distribution Analysis
8.3 Roland
8.3.1 Company Profile
8.3.2 Product Picture and Specifications
8.3.2.1 Product A
8.3.2.2 Product B
8.3.3 Roland 2016 Dental CAD/CAM Milling Machines Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.3.4 Roland 2016 Dental CAD/CAM Milling Machines Business Region Distribution Analysis
8.4 Straumann
8.4.1 Company Profile
8.4.2 Product Picture and Specifications
8.4.2.1 Product A
8.4.2.2 Product B
8.4.3 Straumann 2016 Dental CAD/CAM Milling Machines Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.4.4 Straumann 2016 Dental CAD/CAM Milling Machines Business Region Distribution Analysis
8.5 Zimmer
8.5.1 Company Profile
8.5.2 Product Picture and Specifications
8.5.2.1 Product A
8.5.2.2 Product B
8.5.3 Zimmer 2016 Dental CAD/CAM Milling Machines Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.5.4 Zimmer 2016 Dental CAD/CAM Milling Machines Business Region Distribution Analysis
8.6 Zirkonzahn
8.6.1 Company Profile
8.6.2 Product Picture and Specifications
8.6.2.1 Product A
8.6.2.2 Product B
8.6.3 Zirkonzahn 2016 Dental CAD/CAM Milling Machines Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.6.4 Zirkonzahn 2016 Dental CAD/CAM Milling Machines Business Region Distribution Analysis
8.7 Willemin-Macodel
8.7.1 Company Profile
8.7.2 Product Picture and Specifications
8.7.2.1 Product A
8.7.2.2 Product B
8.7.3 Willemin-Macodel 2016 Dental CAD/CAM Milling Machines Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.7.4 Willemin-Macodel 2016 Dental CAD/CAM Milling Machines Business Region Distribution Analysis
8.8 Dentium
8.8.1 Company Profile
8.8.2 Product Picture and Specifications
8.8.2.1 Product A
8.8.2.2 Product B
8.8.3 Dentium 2016 Dental CAD/CAM Milling Machines Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.8.4 Dentium 2016 Dental CAD/CAM Milling Machines Business Region Distribution Analysis
8.9 Amann Girrbach
8.9.1 Company Profile
8.9.2 Product Picture and Specifications
8.9.2.1 Product A
8.9.2.2 Product B
8.9.3 Amann Girrbach 2016 Dental CAD/CAM Milling Machines Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.9.4 Amann Girrbach 2016 Dental CAD/CAM Milling Machines Business Region Distribution Analysis
8.10 Imes-icore
8.10.1 Company Profile
8.10.2 Product Picture and Specifications
8.10.2.1 Product A
8.10.2.2 Product B
8.10.3 Imes-icore 2016 Dental CAD/CAM Milling Machines Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.10.4 Imes-icore 2016 Dental CAD/CAM Milling Machines Business Region Distribution Analysis
8.11 DATRON
8.12 Schutz Dental
8.13 vhf camfacture
8.14 Yenadent
8.15 B&D Dental
8.16 INTERDENT
8.17 MECANUMERIC
8.18 CadBlu Dental
8.19 Bien-Air Dental
8.20 Reitel Feinwerktechnik

Buy Now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=2785058

Continued….

Contact Us: sales@wiseguyreports.com

Ph: +1-646-845-9349 (US) ; Ph: +44 208 133 9349 (UK)

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Immuno-Oncology (IO)-Competitive Analysis and Market Forecast- [2016-2022]- Report by Polaris Market Research

The growth in the biopharmaceutical industry is predominantly being driven by oncology products which was roughly ~94 Billion USD in 2016”

— Polaris Market Research

BROOKLYN, NY, UNITED STATES, January 31, 2018 /EINPresswire.com/ — The Global Oncology market size is expected to exceed USD 190 billion by 2022. The Immuno-Oncology market was valued at USD 6 billion representing 7% of the global Oncology market in 2016 but is expected to grow at a impressive CAGR of ~30% during the forecast period from 2016-2022 as reported by Polaris Market Research.

The immune-checkpoint blockade, is the revolutionizing treatment options in almost all oncology disease areas which has witnessed the rapid uptake in the growing Oncology market. These therapies are largely dependent on the global immune system of each individual patient, and not necessarily dependent only on the tumor biology which makes it the truly personalized medicine.

As of December 2017, there are 6 Immuno-Oncology therapies which have been launched in the market, with the Opdivo and Keytruda being the highest sales generating drugs. There are dozens of targets being tested across hundreds of clinical trials ongoing for Cancer therapy area as a monotherapy and as combination trials.

Polaris Market Research estimates that with the expected launch of the potential Immuno-Oncology, the market is expected grow at a higher rate. The Unites States accounts for the higher share of the market as compared to the Europe and Japan. The highest market size is subjected to the growth of the two immunotherapies ie Keytruda (Merck) and Opdivo (Bristol Myers Squibb), expansion of these therapies in other cancers and rapid uptake of overall immunotherapies.

On the flip side, with the approval of the immunotherapies, the complexity of cancer treatment in patients as a personalized medicine has also increased. These therapies are thought to be largely dependent on the global immune system of each individual patient, and not necessarily dependent only on the tumor biology. Even the target-specific molecular characteristics of a tumor are only present in a small proportion of patients which are to be cured by immunotherapies. Therefore, new technologies are needed that can help predict which patients will benefit from immunotherapy.

Polaris Market Research has provided the forecasts of the Global Immuno-Oncology Therapies Market from 2016-2022.

The major segments which has been investigated in the global market from 2016-2022 are:

1. Market Analysis by Marketed Immuno-Oncology Therapies
2. Market Analysis by Companies
3. Market Analysis by Indications

The Marketed Therapies undertaken in forecast from 2016-2022 are:

1. Yervoy (Bristol Myers Squibb)
2. Keytruda (Merck)
3. Opdivo (Bristol Myers Squibb)
4. Tecentriq (Roche)
5. Bavencio (Merck/Pfizer)
6. Imfinzi (AstraZeneca)
7. Epacadostat (Incyte Pharmaceuticals)
8. Tremelimumab (AstraZeneca)

The Major Indications in Immuno-Oncology Therapies are:

1. Melanoma
2. Lung Cancer
3. Small Cell Lung Cancer (SCLC)
4. Non-Small Cell Lung Cancer (NSCLC)
5. Head & Neck Squamous Cell Carcinoma (HNSCC)
6. Renal Cell Cancer
7. Bladder Cancer

Leading Companies investigated in the Report are

1. Bristol Myers Squib (BMS)
2. Merck (MRK)
3. AstraZeneca (AZ)
4. Bristol Myers Squib (BMS)
5. Roche Holding AG (RHHBY)
6. Pfizer (PFE)
7. Incyte (INCY)
8. Other Companies

Browse other reports by Polaris Market Research:
https://www.polarismarketresearch.com/industry/Healthcare/

Neel
Polaris Market Research & Consulting
+16465689980
email us here


Source: EIN Presswire